BioNTech SE (NASDAQ:BNTX) reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.
The COVID-19 vaccine maker reported sales of $295.69 million (260.8 million euros), compared to 128.7 million euros a year ago, beating the consensus of $147.90 million.
The sales increase was mainly driven by higher revenues from BioNTech’s COVID-19 vaccine collaboration.
R&D expenses were 509.1 million euros compared to 584.6 million a year ago, mainly driven by the reprioritization of clinical trials towards focus programs.
SG&A expenses decreased to 137.4 million euros, compared to 183.8 million euros a year ago, primarily due to a reduction in external services.
Cash and …